Citigroup’s aTyr Pharma ATYR Stock Holding History

Citigroup’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$537	Sell	900 -4,991	-85%	-$3.26K	﹤0.01%	5457
2026 Q1	$4.59K	Buy	5,891 +2,821	+92%	+$2.38K	﹤0.01%	5281
2025 Q4	$2.4K	Sell	3,070 -2,647	-46%	-$2.17K	﹤0.01%	5426
2025 Q3	$4.12K	Sell	5,717 -27,616	-83%	-$125K	﹤0.01%	5286
2025 Q2	$169K	Buy	33,333 +33,332	+3,333,200%	+$131K	﹤0.01%	4147
2025 Q1	$3	Sell	1 -104,479	-100%	-$381K	﹤0.01%	5515
2024 Q4	$378K	Sell	104,480 -28,503	-21%	-$86.3K	﹤0.01%	4017
2024 Q3	$234K	Buy	+132,983	New	+$242K	﹤0.01%	4237
2024 Q2	–	Sell	-78,620	Closed	-$153K	–	5813
2024 Q1	$153K	Hold	78,620	–	–	﹤0.01%	4128
2023 Q4	$111K	Buy	+78,620	New	+$101K	﹤0.01%	4161
2023 Q1	–	Sell	-428,460	Closed	-$938K	–	5925
2022 Q4	$938K	Buy	+428,460	New	+$1.01M	﹤0.01%	2656
2022 Q2	–	Sell	-650	Closed	-$3K	–	6741
2022 Q1	$3K	Buy	+650	New	+$3.68K	﹤0.01%	5999
2018 Q1	–	Sell	-36	Closed	-$2K	–	7696
2017 Q4	$2K	Sell	36 -485	-93%	-$29.8K	﹤0.01%	7406
2017 Q3	$37K	Sell	521 -36	-6%	-$1.67K	﹤0.01%	6153
2017 Q2	$27K	Hold	557	–	–	﹤0.01%	6145
2017 Q1	$27K	Buy	557 +21	+4%	+$960	﹤0.01%	6093
2016 Q4	$16K	Sell	536 -309	-37%	-$12.7K	﹤0.01%	6612
2016 Q3	$37K	Buy	845 +643	+318%	+$27.8K	﹤0.01%	5861
2016 Q2	$8K	Sell	202 -364	-64%	-$16.9K	﹤0.01%	6647
2016 Q1	$31K	Buy	566 +197	+53%	+$15K	﹤0.01%	6346
2015 Q4	$51K	Buy	369 +364	+7,280%	+$51.8K	﹤0.01%	5931
2015 Q3	$1K	Sell	5 -1	-17%	-$228	﹤0.01%	7233
2015 Q2	$1K	Buy	+6	New	+$1.86K	﹤0.01%	7351

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup's ATYR Position: Q2 2026 in Review

Citigroup reduced its aTyr Pharma (ATYR) stake by 85% in Q2 2026, selling an estimated $3.26K and leaving 900 shares worth $537. The position accounts for ﹤0.01% of the portfolio, ranked #5457.

Citigroup first reported a position in ATYR in Q2 2015 and has held it in 23 quarters since. The position peaked at $938K in Q4 2022. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

Citigroup held 900 shares of aTyr Pharma worth $537 as of Q2 2026.
Citigroup sold 4,991 aTyr Pharma shares in Q2 2026, an estimated $3.26K.
aTyr Pharma made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5457 holding.
Citigroup first reported a position in aTyr Pharma in Q2 2015 and has held it in 23 quarters since.
Citigroup's aTyr Pharma position peaked at $938K in Q4 2022.
90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.